# Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

> **NCT04002934** · PHASE2 · COMPLETED · sponsor: **Riley Bove, MD** · enrollment: 63 (actual)

## Conditions studied

- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Bazedoxifene Acetate

## Key facts

- **NCT ID:** NCT04002934
- **Lead sponsor:** Riley Bove, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-10
- **Primary completion:** 2025-05-13
- **Final completion:** 2025-05-20
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04002934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04002934, "Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04002934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*